Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease

Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α

Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057

Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase

Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073

Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain

DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439

Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation

Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188

Histone Acetyltransferases

Dent, S., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,906

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228

Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null Mice

Lin, J., Wu, P.-H., Tarr, P. T., Lindenberg, K. S., St-Pierre, J., Zhang, C.-Y., Mootha, V. K., Jäger, S., Vianna, C. R., Reznick, R. M., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.013 · Cited by 1,162

Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease

Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123

Peroxisome Proliferator-Activated Receptor γ Coactivator 1 Coactivators, Energy Homeostasis, and Metabolism

Handschin, C., & Spiegelman, B. M. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0037 · Cited by 1,090

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

Xie, N., Zhang, L., Gao, W. Q., Huang, C., Huber, P., Zhou, X., Li, C. L., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,147

NAD+ in Brain Aging and Neurodegenerative Disorders

Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790

Sirt1 and the Mitochondria

Luen Tang, B. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2318 · Cited by 740

SIRT1 in Neurodevelopment and Brain Senescence

Herskovits, A. Z., & Guarente, L. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.028 · Cited by 504

The emerging field of epigenetics in neurodegeneration and neuroprotection

Hwang, J.-Y., Aromolaran, K. A., & Zukin, R. S. (2017) · Nature reviews. Neuroscience · doi:10.1038/nrn.2017.46 · Cited by 353

Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications

Gasperi, V., Sibilano, M., Savini, I., & Catani, M. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040974 · Cited by 286

Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession

Liu, D., Pitta, M., Jiang, H., Lee, J.-H., Zhang, G., Chen, X., Kawamoto, E. M., & Mattson, M. P. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.020 · Cited by 238

Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?

Harrison, I. F., & Dexter, D. T. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.05.010 · Cited by 233

The Influence of Nicotinamide on Health and Disease in the Central Nervous System

Fricker, R. A., Green, E. L., Jenkins, S. I., & Griffin, S. M. (2018) · International Journal of Tryptophan Research · doi:10.1177/1178646918776658 · Cited by 205

SIRT1 and SIRT2 Activity Control in Neurodegenerative Diseases

Manjula, R., Anuja, K., & Alcain, F. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585821 · Cited by 197

New Avenues for the Treatment of Huntington’s Disease

Kim, A. M., Lalonde, K. M., Truesdell, A., Welter, P. G., Brocardo, P. S., Rosenstock, T. R., & Gil‐Mohapel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168363 · Cited by 217

Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment

Hwang, E., & Song, S. (2020) · Biomolecules · doi:10.3390/biom10050687 · Cited by 144

Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis

Ayala‐Peña, S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.017 · Cited by 147

Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington’s Disease Models

Naia, L., Rosenstock, T. R., Oliveira, A. M., Oliveira-Sousa, S. I., Caldeira, G. L., Carmo, C., Laço, M., Hayden, M. R., Oliveira, C. R., & Rego, A. C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0048-3 · Cited by 137

SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington's Disease Phenotypes In Vivo

Bobrowska, A., Dönmez, G., Weiss, A., Guarente, L., & Bates, G. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034805 · Cited by 131

Peroxisome-Proliferator-Activated Receptor Gamma Coactivator 1 Contributes to Dysmyelination in Experimental Models of Huntington's Disease

Xiang, Z., Valenza, M., Cui, L., Leoni, V., Jeong, H.-K., Brilli, E., Zhang, J., Peng, Q., Duan, W., Reeves, S. A., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1291-11.2011 · Cited by 136

The promise and perils of HDAC inhibitors in neurodegeneration

Didonna, A., & Opal, P. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.147 · Cited by 123

Reduced Activity of AMP-Activated Protein Kinase Protects against Genetic Models of Motor Neuron Disease

Lim, M. A., Selak, M. A., Xiang, Z., Krainc, D., Neve, R. L., Kraemer, B. C., Watts, J. L., & Kalb, R. G. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.6554-10.2012 · Cited by 102

PGC-1α sparks the fire of neuroprotection against neurodegenerative disorders

Lv, J., Jiang, S., Yang, Z. P., Hu, W., Wang, Z., Li, T. X., & Yang, Y. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.03.004 · Cited by 102

PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease

Chiang, M., Chern, Y., & Huang, R. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.016 · Cited by 99

D-β-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease

Lim, S., Chesser, A. S., Grima, J. C., Rappold, P. M., Blum, D. L., Przedborski, S., & Tieu, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024620 · Cited by 94

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders

Messer, A. C., & Butler, D. C. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104619 · Cited by 91

Huntington’s Disease

Zuccato, C., & Cattaneo, E. F. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-45106-5_14 · Cited by 94

NAMPT as a Therapeutic Target against Stroke

Wang, P., & Miao, C. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.012 · Cited by 87

Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis

Kumar, A., Vaish, M., & Ratan, R. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.016 · Cited by 82

Histone Deacetylase Inhibitor (HDACi) Suberoylanilide Hydroxamic Acid (SAHA)-mediated Correction of α1-Antitrypsin Deficiency

Bouchecareilh, M., Hutt, D. M., Szajner, P., Flotte, T. R., & Balch, W. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.404707 · Cited by 84

Role of BDNF in Central Motor Structures and Motor Diseases

He, Y., Zhang, X., Yung, W., Zhu, J., & Wang, J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8466-y · Cited by 84

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

Ehrnhoefer, D. E., Wong, B. K. Y., & Hayden, M. R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3556 · Cited by 78

Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide

Song, S. B., Park, J., Chung, G. J., Lee, I. H., & Hwang, E. S. (2019) · Metabolomics · doi:10.1007/s11306-019-1604-4 · Cited by 73

IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4

Huang, Y., Wang, S., Zhou, J., Liu, Y., Du, C., Yang, K., Bi, X., Liu, M., Han, W., Wang, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18519-0 · Cited by 65

Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins

Butler, D. C., McLear, J. A., & Messer, A. C. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.004 · Cited by 63

The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease

Harrison, I. F., Powell, N. M., & Dexter, D. T. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14599 · Cited by 59

B Vitamins and Fatty Acids: What Do They Share with Small Vessel Disease-Related Dementia?

Moretti, R., & Peinkhofer, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225797 · Cited by 60

Transcriptional dysregulation in Huntington’s disease: The role of histone deacetylases

Sharma, S., & Taliyan, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.002 · Cited by 58

Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status

Duan, W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0055-0 · Cited by 54

PGC-1α, Sirtuins and PARPs in Huntington’s Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All

Lloret, A., & Beal, M. F. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02809-1 · Cited by 52

Sirtuins: double players in Huntington's disease

Naia, L., & Rego, A. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.07.003 · Cited by 54

Biological Aging and the Cellular Pathogenesis of Huntington’s Disease

Machiela, E., & Southwell, A. L. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-200395 · Cited by 54

Reelin is a target of polyglutamine expanded ataxin-7 in human spinocerebellar ataxia type 7 (SCA7) astrocytes

McCullough, S. D., Xu, X., Dent, S., Bekiranov, S., Roeder, R. G., & Grant, P. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218331110 · Cited by 47

Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington's disease model

Reynolds, R. H., Petersen, M. H., Willert, C. W., Heinrich, M., Nymann, N., Dall, M., Treebak, J. T., Björkqvist, M., Silahtaroglu, A., Hasholt, L., et al. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.12.009 · Cited by 44

Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future

Hu, M.-L., Pan, Y.-R., Yong, Y.-Y., Liu, Y., Yu, L., Qin, D.-L., Qiao, G., Law, B. Y.-K., Wu, J.-M., Zhou, X.-G., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102078 · Cited by 44

Epigenetics in Nucleotide Repeat Expansion Disorders

He, F., & Todd, P. K. (2011) · Seminars in Neurology · doi:10.1055/s-0031-1299786 · Cited by 45

Prospects for neuroprotective therapies in prodromal Huntington's disease

Chandra, A., Johri, A., & Beal, M. F. (2014) · Movement Disorders · doi:10.1002/mds.25835 · Cited by 41

Metabolism in HD: Still a relevant mechanism?

Duan, W., Jiang, M., & Jin, J. (2014) · Movement Disorders · doi:10.1002/mds.25992 · Cited by 41

The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease

Chiang, M., Chern, Y., & Juo, C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.05.006 · Cited by 41

Aqueous extract of Glycyrrhiza inflata inhibits aggregation by upregulating PPARGC1A and NFE2L2–ARE pathways in cell models of spinocerebellar ataxia 3

Chen, C., Weng, Y., Chen, W.-L., Lin, T., Chao, C., Lin, C., Chen, I., Lee, L., Lin, H.-Y., Wu, Y., et al. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.023 · Cited by 41

Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra

Williams, A. C., Hill, L. J., & Ramsden, D. B. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/302875 · Cited by 42

Neuroprotective Effects of Nicotinamide against MPTP-Induced Parkinson’s Disease in Mice: Impact on Oxidative Stress, Neuroinflammation, Nrf2/HO-1 and TLR4 Signaling Pathways

Rehman, I. U., Khan, A., Ahmad, R., Choe, K., Park, H. Y., Lee, H. J., Atiq, A., Park, J., Hahm, J. R., & Kim, M. O. (2022) · Biomedicines · doi:10.3390/biomedicines10112929 · Cited by 40

Cerebellar transcriptional alterations with Purkinje cell dysfunction and loss in mice lacking PGC-1α

Lucas, E. K., Reid, C. S., McMeekin, L. J., Dougherty, S., Floyd, C. L., & Cowell, R. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00441 · Cited by 41

The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice

Reiner, A., Lafferty, D., Wang, H. B., Mar, N. D., & Deng, Y. P. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.025 · Cited by 38

Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II

Switonski, P. M., Szlachcic, W. J., Gabka, A., Krzyżosiak, W. J., & Figiel, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8316-3 · Cited by 38

Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies

Xiang, C., Zhang, S., Dong, X., Ma, S., & Cong, S. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00153 · Cited by 38

Intrabodies as Neuroprotective Therapeutics

Messer, A. C., & Joshi, S. N. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0193-6 · Cited by 35

Therapeutic Strategies in Huntington’s Disease: From Genetic Defect to Gene Therapy

Jurcău, A., & Jurcău, M. C. (2022) · Biomedicines · doi:10.3390/biomedicines10081895 · Cited by 37

Effect of supplementation of nicotinamide and sodium butyrate on the growth performance, liver mitochondrial function and gut microbiota of broilers at high stocking density

Wu, Y., Wang, Y., Yin, D., Wu, W., Sun, X., Zhang, Y., Guo, X., Chen, J., & Yuan, J. (2019) · Food & Function · doi:10.1039/c9fo00904c · Cited by 38

Transcriptome analysis reveals a molecular understanding of nicotinamide and butyrate sodium on meat quality of broilers under high stocking density

Wu, Y., Wang, Y., Yin, D., Mahmood, T., & Yuan, J. (2020) · BMC Genomics · doi:10.1186/s12864-020-06827-0 · Cited by 33

Mitophagy impairment in neurodegenerative diseases: Pathogenesis and therapeutic interventions

Mani, S., Swargiary, G., & Chadha, R. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.01.001 · Cited by 33

NAD + Precursors in Human Health and Disease: Current Status and Future Prospects

Yaku, K., & Nakagawa, T. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0354 · Cited by 33

Therapeutic approaches targeting aging and cellular senescence in Huntington's disease

Bhat, A. A., Moglad, E. H. O., Afzal, M., Thapa, R., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Ali, H., Pant, K., Singh, T. G., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70053 · Cited by 32

Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum

Ieraci, A., & Herrera, D. G. (2018) · The Cerebellum · doi:10.1007/s12311-017-0916-z · Cited by 31

Neuroprotection of NAD+ and NBP against ischemia/reperfusion brain injury is associated with restoration of sirtuin-regulated metabolic homeostasis

Wang, X., Mao, G.-H., Li, Q., Tang, J., Zhang, H., Wang, K.-L., Wang, L., Ni, H., Sheng, R., & Qin, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1096533 · Cited by 34

Nicotinamide Treatment Facilitates Mitochondrial Fission through Drp1 Activation Mediated by SIRT1-Induced Changes in Cellular Levels of cAMP and Ca2+

Song, S. B., Park, J., Jang, S. Y., & Hwang, E. S. (2021) · Cells · doi:10.3390/cells10030612 · Cited by 31

Critical Role of Astrocyte NAD + Glycohydrolase in Myelin Injury and Regeneration

Langley, M. R., Choi, C., Peclat, T., Guo, Y., Simon, W. L., Yoon, H., Kleppe, L. S., Lucchinetti, C. F., Chini, C. C. S., Chini, E. N., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2264-20.2021 · Cited by 31

NAD+ Metabolism and Diseases with Motor Dysfunction

Lundt, S., & Ding, S. (2021) · Genes · doi:10.3390/genes12111776 · Cited by 27

Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease

Sadan, O., Melamed, E., & Offen, D. (2012) · PLoS Currents · doi:10.1371/4f7f6dc013d4e · Cited by 28

Nicotinamide Administration Improves Remyelination after Stroke

Wang, C., Zhang, Y., Ding, J., Zhao, Z., Qian, C., Luan, Y., & Teng, G. (2017) · Neural Plasticity · doi:10.1155/2017/7019803 · Cited by 28

Vibrational spectroscopic, molecular docking and quantum chemical studies on 6-aminonicotinamide

Asath, R. M., Premkumar, S., Mathavan, T., & Benial, A. M. F. (2016) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2016.12.058 · Cited by 27

Mitochondrial targeted antioxidants as potential therapy for huntington’s disease

Upadhayay, S., & Kumar, P. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00619-z · Cited by 30

Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases

Gomes, P., Leal, H., Mendes, A. F., Reis, F., & Cavadas, C. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.003 · Cited by 27

Progresses in both basic research and clinical trials of NAD+ in Parkinson’s disease

Maria Jose Perez, J., Baden, P., & Deleidi, M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111499 · Cited by 26

Astrocyte Dysfunctions in Obsessive Compulsive Disorder: Rethinking Neurobiology and Therapeutic Targets

Gonzalez, L., & Bezzi, P. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70092 · Cited by 24

Sirtuins as Modifiers of Huntington's Disease (HD) Pathology

Neo, S. H., & Tang, B. L. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.013 · Cited by 25

Epigenetic Explorations of Neurological Disorders, the Identification Methods, and Therapeutic Avenues

Firdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111658 · Cited by 26

Silent information regulator 1 modulator resveratrol increases brain lactate production and inhibits mitochondrial metabolism, whereas SRT1720 increases oxidative metabolism

Rowlands, B. D., Lau, C. L., Ryall, J. G., Thomas, D. S., Klugmann, M., Beart, P. M., & Rae, C. D. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23570 · Cited by 24

Nicotinamide promotes neuronal differentiation of mouse embryonic stem cells in vitro

Griffin, S. M., Pickard, M. R., Orme, R. P., Hawkins, C., & Fricker, R. A. (2013) · Neuroreport · doi:10.1097/wnr.0000000000000071 · Cited by 23

Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models

Chen, C., Chen, W., Hung, C.-T., Lin, T., Lee, M.-C., Chen, I., Lin, C., Chao, C., Wu, Y., Chang, K., et al. (2019) · Aging · doi:10.18632/aging.101804 · Cited by 23

Differential Effect of HDAC3 on Cytoplasmic and Nuclear Huntingtin Aggregates

Mano, T., Suzuki, T., Tsuji, S., & Iwata, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111277 · Cited by 22

Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset

Gardiner, S. L., Milanese, C., Boogaard, M. W., Buijsen, R. A. M., Hogenboom, M., Roos, R. A. C., Mastroberardino, P. G., van Roon‐Mom, W., & Aziz, N. A. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000275 · Cited by 20

Nicotinamide riboside alleviates brain dysfunction induced by chronic cerebral hypoperfusion via protecting mitochondria

Wang, L., Peng, T., Deng, J., Gao, W., Wang, H., Luo, O. J., Huang, L., & Chen, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116272 · Cited by 19

Virtual Screening in the Identification of Sirtuins’ Activity Modulators

Abbotto, E., Scarano, N., Piacente, F., Millo, E., Cichero, E., & Bruzzone, S. (2022) · Molecules · doi:10.3390/molecules27175641 · Cited by 18

Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases

Ferrantelli, F., Chiozzini, C., Leone, P., Manfredi, F., & Federico, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060529 · Cited by 17

Sustainable Design of New Ionic Forms of Vitamin B3 and Their Utilization as Plant Protection Agents

Stachowiak, W., Kaczmarek, D. K., Rzemieniecki, T., & Niemczak, M. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c01807 · Cited by 16

Integration of the Deacetylase SIRT1 in the Response to Nucleolar Stress: Metabolic Implications for Neurodegenerative Diseases

Kreiner, G., Soenmez, A., Liss, B., & Parlato, R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00106 · Cited by 15

Neurodegenerative diseases: Epigenetic regulatory mechanisms and therapeutic potential

Men, J., Wang, X., Zhou, Y., Huang, Y., Zheng, Y., Wang, Y., Yang, S., Chen, N., Yan, N., & Duan, X. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111715 · Cited by 16

Characteristics, Pathophysiology and Clinical Management of Weight Loss in Huntington’s Disease

Aziz, N. A., & Roos, R. A. C. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.22 · Cited by 13

Morbus Huntington

Rollnik, J. D. (2015) · Der Nervenarzt · doi:10.1007/s00115-015-4306-9 · Cited by 13

Risks and rewards of targeting NAD+ homeostasis in the brain

Li, C., & Wu, L. E. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111545 · Cited by 14

Polyglutamine disorders: Pathogenesis and potential drug interventions

Tandon, S., Aggarwal, P., & Sarkar, S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122562 · Cited by 13

Potential therapeutic targets in polyglutamine-mediated diseases

Katsuno, M., Watanabe, H., Yamamoto, M., & Sobue, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.956727 · Cited by 12

The Use of Nicotinamide as a Treatment for Experimental Traumatic Brain Injury and Stroke: A Review and Evaluation

Haar, C. V. (2013) · Clinical Pharmacology & Biopharmaceutics · doi:10.4172/2167-065x.s1-005 · Cited by 12

Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntington’s Disease

Salamon, A., Maszlag-Török, R., Veres, G., Boros, F. A., Vágvölgyi-Sümegi, E., Somogyi, A., Vécsei, L., Klivènyi, P., & Zádori, D. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03069-0 · Cited by 11

Endogenous metabolism in endothelial and immune cells generates most of the tissue vitamin B3 (nicotinamide)

Zeidler, J. D., Chini, C. C. S., Kanamori, K. S., Kashyap, S., Espíndola‐Netto, J. M., Thompson, K. D., Warner, G. M., Cabral, F. S., Peclat, T., Gomez, L. S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105431 · Cited by 11

Brain-Derived Neurotrophic Factor (BDNF) in Huntington’s Disease: Neurobiology and Therapeutic Potential

Azman, K. F., & Zakaria, R. (2025) · Current Neuropharmacology · doi:10.2174/1570159x22666240530105516 · Cited by 10

Therapeutic application of nicotinamide: As a potential target for inhibiting fibrotic scar formation following spinal cord injury

Zhang, C., Shao, Q., Zhang, Y., Liu, W., Kang, J., Jin, Z., Huang, N., & Ning, B. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14826 · Cited by 11

Nicotinamide promotes cardiomyocyte derivation and survival through kinase inhibition in human pluripotent stem cells

Meng, Y., Song, C., Ren, Z., Li, X., Yang, X., Ai, N., Yang, Y., Wang, D., Zhan, M., Wang, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04395-z · Cited by 9

Autophagy–NAD+ axis: emerging insights into neuronal homeostasis and neurodegenerative diseases

Koçak, G., Dimas, M. M., Silva, L., Silva-Amaral, D., Sun, C., Cruddas, S., Barrett, T. G., Martins‐de‐Souza, D., Cunha‐Neto, E., Brocardo, P. S., et al. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1695486 · Cited by 8

Dietary NMN supplementation enhances motor and NMJ function in ALS

Lundt, S., Zhang, N., Polo‐Parada, L., Wang, X., & Ding, S. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114698 · Cited by 9

Increased Mortality in Mice following Immunoprophylaxis Therapy with High Dosage of Nicotinamide in Burkholderia Persistent Infections

Micheva‐Viteva, S., Ross, B. N., Gao, J., Adikari, S., Zhang, P., Mourant, J. R., Wu, T. H., Werner, J. H., Torres, A. G., & Hong‐Geller, E. (2018) · Infection and Immunity · doi:10.1128/iai.00592-18 · Cited by 8

CRISPR-Cas9 mediated genome editing of Huntington’s disease neurospheres

Han, J. Y., Seo, J., Choi, Y., Im, W., Ban, J., & Sung, J. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08175-6 · Cited by 8

Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome

Tremolizzo, L., Rodriguez‐Menendez, V., Conti, E., Zoia, C., Cavaletti, G., & Ferrarese, C. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990535 · Cited by 7

Amitriptyline Improves Motor Function via Enhanced Neurotrophin Signaling and Mitochondrial Functions in the Murine N171-82Q Huntington Disease Model

Cong, W., Chadwick, W., Wang, R., Daimon, C. M., Cai, H., Amma, J., Wood, W. H., Becker, K. G., Martin, B., & Maudsley, S. R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.588608 · Cited by 22

Brain‐derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease

Pineda, J. R., Canals, J. M., Bosch, M., Adell, A., Mengod, G., Artigas, F., Ernfors, P., & Alberch, J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03047.x · Cited by 69

Brain‐derived neurotrophic factor over‐expression in the forebrain ameliorates Huntington’s disease phenotypes in mice

Gharami, K., Xie, Y., An, J. J., Tonegawa, S., & Xu, B. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05137.x · Cited by 184

Effect of chronic metformin treatment in a mouse model of Huntington's disease

Adhihetty, P. J., Iorio, L., Hennessy, T., Ho, D. J., Calingasan, N. Y., Yang, W. X., & Beal, F. M. (2010) · The FASEB Journal · doi:10.1096/fasebj.24.1_supplement.lb683

Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration

Weydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.004 · Cited by 562